



## Novel Therapeutic Approaches in Urothelial Carcinoma

Guest Editors:

**Dr. Mimma Rizzo**

Division of Medical Oncology,  
Azienda Ospedaliero  
Universitaria Consorziata  
Policlinico di Bari, Bari, Italy

**Dr. Patrizia Giannatempo**

Department of Medical Oncology,  
Fondazione I.R.C.C.S. Istituto  
Nazionale dei Tumori, Milan, Italy

Deadline for manuscript  
submissions:  
**closed (30 March 2024)**

### Message from the Guest Editors

Recently, diagnostic and therapeutic advances have led to lower mortality rates for urothelial carcinoma (UC) patients. The standard of care for advanced UC remains platinum-based combination chemotherapy. However, the therapeutic landscape has been expanded with the Food and Drug Administration's approval of erdafitinib for tumors with a mutation or fusion, which activates fibroblast growth factor receptor (FGFR) 2/FGFR3. Enfortumab vedotin and sacituzumab govitecan are indicated after progression to platinum-based chemotherapy and programmed cell death inhibitor 1/ligand 1.

The increasing number of long-term responders to systemic treatments requires early identification and appropriate management of toxicities.

The next step is the analysis of somatic and germline genomics, aimed at the development of therapies directed at tumor-specific, druggable genetic targets. Identification of specific biomarkers is crucial for developing therapeutic strategies for UC patients.

We invite you to submit papers:

- Genomic and molecular characterization;
- Identification of prognostic and predictive biomarkers;
- Therapeutic perspectives;
- Management of emerging therapies.





# medicina

IMPACT  
FACTOR  
2.4

Indexed in:  
PubMed

CITESCORE  
3.3

an Open Access Journal by MDPI

## Editor-in-Chief

### **Prof. Dr. Edgaras Stankevičius**

Medical Academy, Lithuanian  
University of Health Sciences,  
Kaunas, Lithuania

## Message from the Editor-in-Chief

You are invited to contribute a research article or a comprehensive review for consideration and publication in *Medicina* (ISSN: 1648-9144). *Medicina* is an open access, peer-reviewed scientific journal that publishes original articles, critical reviews, research notes, and short communications on medicine. The scientific community and the general public can access the content free of charge as soon as it is published.

## Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, and other databases.

**Journal Rank:** JCR - Q1 (Medicine, General and Internal) / CiteScore - Q1 (General Medicine)

## Contact Us

---

*Medicina* Editorial Office  
MDPI, St. Alban-Anlage 66  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/medicina](http://mdpi.com/journal/medicina)  
[medicina@mdpi.com](mailto:medicina@mdpi.com)